litlas
Log inCreate account

David M. O’Malley

Active 1979–2026

Also published as
David M O'Malley · David M O’Malley · David M. O'Malley
198
Papers
25,607
Citations
87
h-index
183
i10-index

Citations

Citations per year for David M. O’Malley1981: 1 citations1982: 3 citations1983: 2 citations1984: 1 citations1985: 1 citations1986: 2 citations1987: 1 citations1988: 2 citations1989: 3 citations1990: 6 citations1991: 4 citations1992: 17 citations1993: 10 citations1994: 21 citations1995: 23 citations1996: 34 citations1997: 28 citations1998: 40 citations1999: 49 citations2000: 30 citations2001: 51 citations2002: 47 citations2003: 56 citations2004: 51 citations2005: 31 citations2006: 43 citations2007: 36 citations2008: 47 citations2009: 51 citations2010: 60 citations2011: 46 citations2012: 50 citations2013: 34 citations2014: 52 citations2015: 61 citations2016: 69 citations2017: 136 citations2018: 186 citations2019: 768 citations2020: 1,037 citations2021: 1,006 citations2022: 1,077 citations2023: 1,016 citations2024: 1,627 citations2025: 836 citations2026: 20 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,312 citing papers, 23.9% of this breakdownChina: 1,054 citing papers, 10.9% of this breakdownUnited Kingdom: 674 citing papers, 6.9% of this breakdownItaly: 616 citing papers, 6.4% of this breakdownFrance: 485 citing papers, 5% of this breakdownSpain: 404 citing papers, 4.2% of this breakdownCanada: 402 citing papers, 4.1% of this breakdownGermany: 359 citing papers, 3.7% of this breakdownJapan: 301 citing papers, 3.1% of this breakdownAustralia: 260 citing papers, 2.7% of this breakdownNetherlands: 241 citing papers, 2.5% of this breakdownBelgium: 208 citing papers, 2.1% of this breakdown
0%23.9%Other 24.5%

Institutions

Fields

  • Medicine65.8%
  • Biochemistry, Genetics and Molecular Biology21.7%
  • Agricultural and Biological Sciences5.1%
  • Engineering2.3%
  • Immunology and Microbiology2.3%
  • Materials Science0.7%
  • Other2.1%

Topics

  • Ovarian cancer diagnosis and treatment10.2%
  • PARP inhibition in cancer therapy9.3%
  • Endometrial and Cervical Cancer Treatments5.6%
  • DNA Repair Mechanisms3.1%
  • Cancer Immunotherapy and Biomarkers2.7%
  • BRCA gene mutations in cancer2.6%
  • Other66.5%

Coauthors

All papers

Open in search
  1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, Val Gebski, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedländer, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray‐Coquard, Susana Banerjee, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Patricia Pautier, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson and 21 more - The Lancet Oncology 2017 cited by 1,863

  2. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Jesús García-Donás, Elizabeth M. Swisher, Anne Floquet, Gottfried E. Konecny, Iain A. McNeish, Clare L. Scott, T. Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline A. Grace, Thomas C. Harding, Mitch Raponi, James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian and 17 more - The Lancet 2017 cited by 1,704

  3. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

    Authors: David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier, Aurélien Marabelle, Aaron R. Hansen, A. De Jesus Acosta, Wilson H. Miller, Tamar Safra, Antoîne Italiano, Linda Mileshkin, Lei Xu, Fan Jin, Kevin Norwood, Michele Maio - Journal of Clinical Oncology 2022 cited by 498

  4. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

    Authors: Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, David M. O’Malley, Ana Oaknin, Michelle Wilson, Robert L. Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkıran, Olga Mikheeva, Oladapo Yeku, Anita Chudecka-Głaz, Michael Schenker, Ramey D. Littell, Tamar Safra, Hung‐Hsueh Chou, Mark A. Morgan, Vít Drochýtek, Joyce N. Barlin, Toon Van Gorp, Frederick R. Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile Catherine Collins, Kathleen N. Moore, Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit - Journal of Clinical Oncology 2022 cited by 384

  5. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    Authors: Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 cited by 394

  6. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

    Authors: Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria C. DeRosa, Eric Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel N. Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Joyce F. Liu, Haider Mahdi, Lainie P. Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac‐Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsíros, Jennifer L. Burns, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2021 cited by 713

  7. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Authors: Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, Clare L. Scott, Heidi Giordano, James Sun, Gottfried E. Konecny, Robert L. Coleman, Anna V. Tinker, David M. O’Malley, Rebecca Kristeleit, Ling Ma, Katherine M. Bell‐McGuinn, James D. Brenton, Janiel M. Cragun, Ana Oaknin, Isabelle Ray‐Coquard, Maria I. Harrell, Elaina Mann, Scott H. Kaufmann, Anne Floquet, Alexandra Léary, Thomas C. Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R. Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A. McNeish - The Lancet Oncology 2016 cited by 1,200

  8. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, Rebecca Asher, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedländer, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S. Sonke, Alla Lisyanskaya, Jae‐Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth Lowe, Philip Rowe, Ignace Vergote, Éric Pujade-Lauraine, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano and 23 more - The Lancet Oncology 2021 cited by 416

  9. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

    Authors: Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Jubilee Brown, Cara Mathews, Joshua Z. Press, Renaud Sabatier, David M. O’Malley, Vanessa Samouëlian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles A. Leath, Wei Guo, Ellie Im, S. Zildjian, Xinwei Han, Tao Duan, Jennifer Veneris, Bhavana Pothuri - Journal for ImmunoTherapy of Cancer 2022 cited by 322

  10. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Authors: Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray‐Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O’Malley, Setsuko K. Chambers, Scott H. Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James Sun, Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish, Elizabeth M. Swisher - Cancer Discovery 2018 cited by 432

  11. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance

    Authors: Debra L. Richardson, Ramez N. Eskander, David M. O’Malley - JAMA Oncology 2023 cited by 213

  12. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

    Authors: David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska - Journal of Clinical Oncology 2021 cited by 186

  13. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

    Authors: Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Osama Abdelghany, Setsuko K. Chambers, Angeles Alvarez Secord, Laura J. Havrilesky, David M. O’Malley, Floor Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William J. Lowery, Karim ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan‐Arin Silasi, Peter E. Schwartz, Alessandro D. Santin - Journal of Clinical Oncology 2018 cited by 525

  14. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

    Authors: David M Gershenson, Austin Miller, William E Brady, James Paul, Karen Carty, William Rodgers, David Millan, Robert L Coleman, Kathleen N Moore, Susana Banerjee, Kate Connolly, Angeles Alvarez Secord, David M O'Malley, Oliver Dorigo, Stephanie Gaillard, Hani Gabra, Brian Slomovitz, Parviz Hanjani, John Farley, Michael Churchman, Ailith Ewing, Robert L Hollis, C Simon Herrington, Helen Q Huang, Lari Wenzel, Charlie Gourley - The Lancet 2022 cited by 222

  15. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

    Authors: Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Osama Abdelghany, Setsuko K. Chambers, Angeles Alvarez Secord, Laura J. Havrilesky, David M. O’Malley, Floor Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William J. Lowery, Karim ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, Alessandro D. Santin - Clinical Cancer Research 2020 cited by 308

  16. openalex_id:w4226022025

    Authors: David M. Gershenson, Austin Miller, William E. Brady, James Paul, Karen Carty, William H. Rodgers, David Millan, Robert L. Coleman, Kathleen N. Moore, Susana Banerjee, Kate Connolly, Angeles Alvarez Secord, David M. O’Malley, Oliver Dorigo, Stéphanie Gaillard, Hani Gabra, Brian M. Slomovitz, Parviz Hanjani, John Farley, Michael Churchman, Ailith Ewing, Robb Hollis, C. Simon Herrington, Helen Huang, Lari Wenzel, Charlie Gourley cited by 180

  17. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    Authors: Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel - The Lancet Oncology 2017 cited by 602

  18. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Authors: Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David M. O’Malley - Gynecologic Oncology 2023 cited by 108

  19. PARP Inhibitors in Ovarian Cancer: A Review

    Authors: David M. O’Malley, Thomas C. Krivak, Nashwa Kabil, Jiefen Munley, Kathleen N. Moore - Targeted Oncology 2023 cited by 180

  20. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

    Authors: Daniela Matei, Virginia L. Filiaci, Marcus E. Randall, David G. Mutch, Margaret M. Steinhoff, Paul DiSilvestro, Katherine Moxley, Yong M. Kim, Matthew A. Powell, David M. O’Malley, Nick M. Spirtos, William Small, Krishnansu S. Tewari, William E. Richards, John Nakayama, Ursula A. Matulonis, Helen Huang, David S. Miller - New England Journal of Medicine 2019 cited by 467

  21. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Authors: Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin, Anna V. Tinker, Nelson N.H. Teng, Maria I. Harrell, Michael J. Kuiper, Gwo‐Yaw Ho, Holly E. Barker, Maria Jasin, Rohit Prakash, Elizabeth M. Kass, Meghan R. Sullivan, Gregory J. Brunette, Kara A. Bernstein, Robert L. Coleman, Anne Floquet, Michael Friedländer, Ganessan Kichenadasse, David M. O’Malley, Amit M. Oza, James Sun, Liliane Robillard, Lara Maloney, David D.L. Bowtell, Heidi Giordano, Matthew J. Wakefield, Scott H. Kaufmann, Andrew D. Simmons, Thomas C. Harding, Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, Kevin Lin, Clare L. Scott - Cancer Discovery 2017 cited by 417

  22. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

    Authors: Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray‐Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Léary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin Lin, Iain A. McNeish - Nature Communications 2021 cited by 205

  23. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

    Authors: Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D. Galsky, Erika Hamilton, Hidetoshi Hayashi, Guy Jérusalem, Seung Tae Kim, Keun‐Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J. Monk, Danny Nguyen, Do‐Youn Oh, Alicia Okines, David M. O’Malley, Paula R. Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cédric van Marcke, Evan Y. Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas E. Stinchcombe, Tanios Bekaii‐Saab - Journal of Clinical Oncology 2023 cited by 100

  24. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

    Authors: David M. O’Malley, Ana Oaknin, Bradley J. Monk, Frédèric Selle, Carlos A. Rojas, Laurence Gladieff, Dominique Berton, Alexandra Léary, Kathleen N. Moore, Maria Del Pilar Estevez-Diz, Anne‐Claire Hardy‐Bessard, Jérôme Alexandre, Christina Pimentel Opperman, Carla Rameri Alexandre Silva de Azevedo, Leslie M. Randall, Waldo Ortuzar Feliu, Marek Ancukiewicz, Isabelle Ray‐Coquard - Gynecologic Oncology 2021 cited by 127